Filing Details
- Accession Number:
- 0001171843-22-007662
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-25 16:41:02
- Reporting Period:
- 2022-11-22
- Accepted Time:
- 2022-11-25 16:41:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1738021 | Compass Therapeutics Inc. | CMPX | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1814093 | Vered Bisker-Leib | C/O Compass Therapeutics, Inc. 80 Guest St., Suite 601 Boston MA 02135 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-11-22 | 14,929 | $4.19 | 1,069,985 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-11-23 | 9,569 | $4.30 | 1,060,416 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-11-25 | 2 | $4.36 | 1,060,414 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
- The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.30 per share on November 22, 2022 and $4.15 to $4.43 on November 23, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.